Biotechnology firm Insilico Medicine announced that its executive leadership will participate in international investor and technology gatherings in London and Dubai to present recent advancements in artificial intelligence-driven therapeutics and laboratory automation, according to Bioengineer.org. The scheduled presentations highlight how the combination of generative algorithms and automated robotics accelerates target discovery and candidate optimization.
In the United Arab Emirates, Dr. Alex Aliper, Co-Founder and President of Insilico Medicine, will take part in Dubai Future Week, hosted by the Dubai Future Foundation. On November 20, Dr. Aliper is scheduled to deliver a keynote presentation titled "Generative AI and Laboratory Automation for Drug Discovery and Longevity," detailing the company's closed-loop architecture that combines proprietary generative AI algorithms with automated robotic laboratories.
In London, Dr. Alex Zhavoronkov, Founder and Chief Executive Officer of Insilico Medicine, has been invited to speak at the Jefferies Global Healthcare Conference 2026. Dr. Zhavoronkov will deliver a keynote address and join the China Biotech Panel on November 18 to discuss AI methodologies in pharmaceutical discovery and translational research in China's biopharmaceutical industry. He is also scheduled to take part in a China Biotech panel at the UBS Biopharma Conference on November 17.
Insilico Medicine, listed on the Main Board of the Hong Kong Stock Exchange under stock code 03696.HK, utilizes its Pharma.AI platform across disease areas including fibrosis, oncology, immunology, pain, and metabolic disorders, while expanding into materials, agriculture, nutrition, and veterinary sciences.
Sources
- Bioengineer.org · 2026-11-14



